Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.
暂无分享,去创建一个
Sunil V. Rao | R. Califf | E. Antman | H. White | K. Mahaffey | G. Levine | R. Becker | S. Goodman | R. Harrington | D. Gallup | S. Spinler | R. Gallo | J. Ferguson | Marc Cohen | J. Ducas | L. Biasucci | J. Col | S. Rao
[1] A. Coats,et al. Ethical authorship and publishing. , 2009, International journal of cardiology.
[2] S. Yusuf,et al. Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in NonST-Segment Elevation Acute Coronary Syndromes , 2007, Annals of Internal Medicine.
[3] Adelaide,et al. Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.
[4] S. Urien,et al. Dosing Strategy in Patients with Renal Failure Receiving Enoxaparin for the Treatment of non‐ST‐segment Elevation Acute Coronary Syndrome , 2005, Clinical pharmacology and therapeutics.
[5] E. Topol,et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). , 2005, The American journal of cardiology.
[6] R. Califf,et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. , 2004, JAMA.
[7] A. Jacobs,et al. Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention , 2003 .
[8] E. Antman,et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. , 2003, Journal of the American College of Cardiology.
[9] Bertram L Kasiske,et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.
[10] E. Antman,et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. , 2003, American heart journal.
[11] E. Braunwald,et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). , 2002, The American journal of cardiology.
[12] GlYcoprotein IIb,et al. The SYNERGY trial: study design and rationale. , 2002, American heart journal.
[13] E. Antman,et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. , 2002, American heart journal.
[14] M. Bell,et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. , 2002, Journal of the American College of Cardiology.
[15] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .